Legislation

Understanding the nexus approach: R&D expenditure and Patent Box claims

·7 min read

Since 2016, the Patent Box regime has operated under the OECD nexus approach, which links the proportion of qualifying profits to the level of R&D expenditure incurred by the claimant company. We explain how this works in practice.

The nexus approach was introduced into the UK Patent Box regime in 2016, following agreement at OECD level that preferential IP regimes should be linked to substantive economic activity in the jurisdiction offering the relief. The aim was to prevent companies from simply parking IP in low-tax territories without conducting meaningful R&D there.

Under the nexus approach, the proportion of qualifying IP profits that can benefit from the 10% Patent Box rate is determined by the nexus fraction, which compares the company's qualifying R&D expenditure to its total expenditure on developing the relevant IP.

Qualifying expenditure (the numerator) includes expenditure on R&D carried out by the company itself, and expenditure on R&D subcontracted to unconnected third parties. A 30% uplift is applied to the qualifying expenditure figure, subject to a cap at total expenditure, to provide some headroom for connected-party subcontracting.

Non-qualifying expenditure (which reduces the fraction) includes expenditure on R&D subcontracted to connected parties, and the cost of acquiring the IP itself. This means that companies which have purchased patents from group companies, or which rely heavily on connected-party R&D, will find their Patent Box benefit reduced, sometimes significantly.

The nexus fraction is calculated separately for each IP right, or for a sub-stream of IP rights where the company elects to group them. Getting the streaming right is important: grouping IP with very different nexus fractions can dilute the overall benefit, while streaming them separately preserves the full relief on high-nexus IP.

Companies that have historically subcontracted R&D to connected parties should not assume that the Patent Box is unavailable to them. The 30% uplift, combined with careful streaming, can still produce a meaningful benefit. A detailed review of R&D expenditure records, often going back several years, is typically required to establish the correct nexus fractions and quantify the available relief.

Ready to explore your Patent Box position?

Our specialists can assess your eligibility and quantify the relief available to your company.